Genomes and Genes
Bruce C Cree
Affiliation: University of California
- Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosisBruce A C Cree
Department of Neurology, UCSF Medical Center, USA
Mult Scler 19:835-43. 2013..This review assembles the most current information on the reproductive safety of approved and emerging DMTs drawn from the literature and information supplied by the manufacturers...
- Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL dataBruce A C Cree
UCSF Multiple Sclerosis Center, Department of Neurology, University of California, San Francisco, 94117, USA
Arch Neurol 68:464-8. 2011..Because patients of African descent may be less responsive to interferon beta treatment than patients of white race/ethnicity, the efficacy of natalizumab therapy in this population is clinically important...
- Neuromyelitis optica: diagnosis, pathogenesis, and treatmentBruce Cree
Multiple Sclerosis Center, University of California San Francisco, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
Curr Neurol Neurosci Rep 8:427-33. 2008..This review discusses the discovery of the NMO-IgG biomarker, the identification of AQP4 as its target, the clinical applications of these advances, the pathologic implications for the anti-AQP4 antibody, and advances in NMO treatment...
- Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLABruce A C Cree
Department of Neurology, University of California San Francisco, USA
Arch Neurol 66:226-33. 2009....
- Pilot trial of low-dose naltrexone and quality of life in multiple sclerosisBruce A C Cree
Multiple Sclerosis Center at University of California, San Francisco, 94117, USA
Ann Neurol 68:145-50. 2010..To evaluate the efficacy of 4.5mg nightly naltrexone on the quality of life of multiple sclerosis (MS) patients...
- A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01Bruce A C Cree
Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
PLoS ONE 5:e11296. 2010..Whether other major histocompatibility complex (MHC) genes contribute to MS susceptibility is controversial...
- Emerging monoclonal antibody therapies for multiple sclerosisBruce Cree
Multiple Sclerosis Center at UCSF, San Francisco, California 94117, USA
Neurologist 12:171-8. 2006..Because of their accessibility, proteins expressed on the surface of immune system cell lineages are appealing targets for monoclonal antibody therapies...
- Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosisTil Menge
Department of Neurology, University of California San Francisco, San Francisco, CA 94143 0114, USA
J Allergy Clin Immunol 116:453-9. 2005..Galactocerebroside, the major glycolipid of central nervous system myelin, is a known target for pathogenic demyelinating antibody responses in experimental allergic encephalomyelitis (EAE), the animal model of multiple sclerosis (MS)...
- Risk alleles for multiple sclerosis identified by a genomewide studyDavid A Hafler
Division of Molecular Immunology, Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, and Harvard Medical School, Boston, USA
N Engl J Med 357:851-62. 2007..Multiple sclerosis has a clinically significant heritable component. We conducted a genomewide association study to identify alleles associated with the risk of multiple sclerosis...
- Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialKathleen Hawker
Department of Neurology, The Ohio State University Medical Center, Columbus, USA
Ann Neurol 66:460-71. 2009..We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks...
- Correlating Multiple Sclerosis Phenotypes with GenotypesBruce Cree; Fiscal Year: 2007....